NextCure Inc expected to post a loss of $1.93 a share - Earnings Preview

NextCure

03/08/2026 12:38

NextCure Inc NXTC.OQ NXTC.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for NextCure Inc is for a loss of $1.93 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had fallen by about 16.2% in the last three months. ​
Wall Street's median 12-month price target for NextCure Inc is $17.50, about 322.2% above its last closing price of $4.15
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-2.13
-2.10
-1.87
Beat
11.1
Dec. 31 2026
-2.50
-2.42
-0.81
Beat
66.5
Sep. 30 2025
-4.01
-3.98
-3.22
Beat
19.2​
Jun. 30 2025
-4.61
-4.61
-11.29
Missed
-144.6
​​Mar. 31 2025
-4.85
-4.80
-4.68
Beat
2.5
Dec. 31 2024
-3.90
-4.02
-4.92
Missed
-22.4​
Sep. 30 2024
-4.44
-4.14
-4.92
Missed
-18.8
Jun. 30 2024
-4.55
-4.52
-6.60
Missed
-46
This summary was machine generated August 3 at 11:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)